Researchers are evaluating Lyell's CD19/20 dual-targeting CAR-T against marketed CD19 CAR T-cell therapies in the second-line refractory large B-cell lymphoma setting.

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Ultragenyx recently resubmitted a BLA seeking approval for the gene therapy after the FDA rejected it, and the firm will resubmit it again in response to new questions.

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.